Navigation Links
NYU Langone Medical Center Study Shows VNS Therapy is a Safe and Effective Treatment for Refractory Epilepsy

BOSTON and HOUSTON, Dec. 4 /PRNewswire-FirstCall/ -- AES Annual Meeting, Booth #901-- Cyberonics, Inc. (Nasdaq: CYBX) announced today that Vagus Nerve Stimulation (VNS) Therapy, the only FDA-approved implantable medical device for the treatment of refractory epilepsy, will be featured in 14 presentations at the American Epilepsy Society's (AES) Annual Meeting, taking place December 4-8 at the Hynes Convention Center in Boston, Massachusetts.

Robert Elliott, M.D., chief resident of Neurosurgery at NYU Langone Medical Center, will present results of the study entitled, "Vagus Nerve Stimulation for Refractory Epilepsy: Single Surgeon Experience of over 700 Consecutive Operations," on Monday, December 7 at 4:00 p.m. The study was designed to analyze the efficacy and safety of VNS Therapy in a large series of consecutive adults and children with medically refractory epilepsy.

Dr. Elliott and his colleagues at NYU Langone Medical Center conducted a retrospective review of 507 consecutive patients with refractory epilepsy who underwent a total of 720 VNS-related procedures between November 1997 and April 2008. Outcome analysis was performed on 436 patients who underwent primary implantation at the center and had at least one year of follow-up since implantation. Duration of VNS Therapy ranged from one week to 11.35 years.

The results showed a more than 50 percent reduction in seizure frequency occurred in 64.6 percent of patients and 42.1 percent of patients experienced more than a 70 percent reduction in seizure frequency. Patients who had failed intracranial epilepsy procedures prior to VNS Therapy had similar outcomes to those who did not have prior surgery. There were no significant differences in efficacy between adults and children.

"Our study reviewing more than 700 consecutive VNS Therapy procedures further confirms the safety and efficacy of VNS Therapy for medically refractory epilepsy," said Dr. Elliot. "Patients evaluated in this study varied in age, seizure frequency and treatment histories, and the vast majority of patients saw significant improvements in their seizure control. VNS Therapy continues to be an effective way to treat medically refractory epilepsy while possibly improving the quality-of-life for patients."

"Dr. Elliott's study reaffirms the safety, efficacy and quality-of-life benefits of VNS Therapy," said Dan Moore, president and CEO of Cyberonics. "Worldwide, more than 50,000 patients with epilepsy have received VNS Therapy, and a significant majority of these patients are consistently opting to continue treatment, which is evidenced by an initial reimplant rate that exceeds 70 percent. These findings further establish VNS Therapy as the best option for patients with medically refractory epilepsy who are not candidates for resective surgery or who have failed resective surgery."

About Cyberonics, Inc. and VNS Therapy(® )

Cyberonics, Inc. (Nasdaq: CYBX) is a medical technology company with core expertise in neuromodulation. The company developed and markets the VNS Therapy System, which is FDA-approved for the treatments of refractory epilepsy and treatment-resistant depression. The VNS Therapy System uses a surgically implanted medical device that delivers pulsed electrical signals to the vagus nerve. Cyberonics markets the VNS Therapy System in selected markets worldwide.

Additional information on Cyberonics, Inc. and VNS Therapy is available at and

Helen Shik or Amanda Lazaro Connolly
Schwartz Communications

SOURCE Cyberonics, Inc.

SOURCE Cyberonics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Kenneth G. Langone, Home Depot Co-Founder, Chairman of the NYU Langone Medical Center, to Lead 65th Annual Columbus Day Parade as Grand Marshal
2. NYU Langone Medical Centers tip sheet to the 45th Annual Meeting of ASCO
3. NYU Langone Medical Center study shows that cochlear implant surgery is safe for the elderly
4. SIRIUS Satellite Radio & NYU Langone Medical Center Launch Doctor Radio Channel
5. NYU Langone Medical Centers tip sheet to the 44th annual meeting of ASCO
6. North American Seminars Inc. Opens Its 2010 Physical Therapy Continuing Medical Education Course Sponsorship Program
7. IntelliSoft Group Focuses on Protecting Customer Investment in Medical Credentialing Systems -- Budget Constraints and Forced Upgrades in Medical Credentialing Automation
8. Florida Medical Association Marks Record Membership Growth
9. Topping Out Ceremony Marks Milestone in Construction of University Medical Center of Princeton at Plainsboro
10. Chiltern Names Dr. Sharon Moore as Executive VP, Global Quality & Medical Affairs
11. Personality predicts success in medical school, says new study by U of Minnesota professor
Post Your Comments:
(Date:11/28/2015)... ... ... Pixel Film Studios is back again with ProPanel: Pulse . With ... Users have full control over angle of view, speed method, start point, end point, ... get heads to turn. , ProPanel: Pulse offers fully customizable pulsating shape masks, all ...
(Date:11/27/2015)... ... November 27, 2015 , ... The rapid speed ... As people age, more care is needed, especially with Alzheimer’s, dementia and other ... are being overworked. The forgotten part of this equation: 80 percent of medical ...
(Date:11/27/2015)... ... November 27, 2015 , ... The ... of USA Today in Atlanta, Dallas, New York, Minneapolis, South Florida, with a ... component is distributed nationally, through a vast social media strategy and across a ...
(Date:11/27/2015)... ... November 27, 2015 , ... A simply groundbreaking television series, "Voices in America", ... delves into an array of issues that are presently affecting Americans. Dedicated to providing ... this show is changing the subjects consumers focus on, one episode at a time. ...
(Date:11/27/2015)... ... November 27, 2015 , ... Dr. Thomas Dunlap and Dr. ... Tucker Bierbaum with Emergency Medicine at St., Joseph Health System’s Santa Rosa Memorial ... conditions present in similar ways and require time-critical intervention to avoid large area heart ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... Nov. 26, 2015 Research and Markets ... the "2016 Future Horizons and Growth Strategies ... Supplier Shares, Country Segment Forecasts, Competitive Intelligence, Emerging ... --> --> This ... the Japanese therapeutic drug monitoring market, including emerging ...
(Date:11/26/2015)... -- Research and Markets ( ) has announced ... by Type (Dressings, Therapy Devices, Active Wound Care), Application ... and Geography - Global Forecast to 2020" report ... --> The purpose of this report is ... global advanced wound care market. It involves deep dive ...
(Date:11/26/2015)... ) has ... Market by Type (Reagents & Kits, Analyzers), ... Diagnostic Labs), Application (Research, Clinical Diagnostics), and ... report to their offering. --> ... the "Radioimmunoassay Market by Type (Reagents ...
Breaking Medicine Technology: